Arbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B

Reuters11-13

<a href="https://laohu8.com/S/ABUS">Arbutus Biopharma</a> Unveils Progress Toward Functional Cure for Chronic Hepatitis B

Arbutus Biopharma Corp. has provided an update on its ongoing efforts to develop treatments for chronic hepatitis B (cHBV). The company highlighted progress with its lead siRNA therapeutic candidate, imdusiran, which demonstrated durable viral suppression and multiple functional cures in a Phase 2a clinical trial. The data showed meaningful reductions in both HBsAg and HBV DNA, with some patients able to discontinue therapy. Imdusiran was generally safe and well tolerated in the studies presented. Arbutus also reported a strong financial position, with cash and cash equivalents totaling $94 million as of September 30, 2025. The company is evaluating development plans for a Phase 2b clinical trial of imdusiran and continues to advance its immunotherapy program, including the oral PD-L1 inhibitor AB-101. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583672355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583672355","market":"nz","top_or_hot":-1,"title":"Arbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> Unveils Progress Toward Functional Cure for Chronic Hepatitis B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arbutus Biopharma Corp. has provided an update on its ongoing efforts to develop treatments for chronic hepatitis B (cHBV). The company highlighted progress with its lead siRNA therapeutic candidate, imdusiran, which demonstrated durable viral suppression and multiple functional cures in a Phase 2a clinical trial. The data showed meaningful reductions in both HBsAg and HBV DNA, with some patients able to discontinue therapy. Imdusiran was generally safe and well tolerated in the studies presented. Arbutus also reported a strong financial position, with cash and cash equivalents totaling $94 million as of September 30, 2025. The company is evaluating development plans for a Phase 2b clinical trial of imdusiran and continues to advance its immunotherapy program, including the oral PD-L1 inhibitor AB-101. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> Unveils Progress Toward Functional Cure for Chronic Hepatitis B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arbutus Biopharma Corp. has provided an update on its ongoing efforts to develop treatments for chronic hepatitis B (cHBV). The company highlighted progress with its lead siRNA therapeutic candidate, imdusiran, which demonstrated durable viral suppression and multiple functional cures in a Phase 2a clinical trial. The data showed meaningful reductions in both HBsAg and HBV DNA, with some patients able to discontinue therapy. Imdusiran was generally safe and well tolerated in the studies presented. Arbutus also reported a strong financial position, with cash and cash equivalents totaling $94 million as of September 30, 2025. The company is evaluating development plans for a Phase 2b clinical trial of imdusiran and continues to advance its immunotherapy program, including the oral PD-L1 inhibitor AB-101. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABUS","symbol_name":"Arbutus Biopharma Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLc7lsnt:1","article_id":"2583672355","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583672355","pubTimestamp":1763037474,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arbutus Biopharma Corp. has provided an update on its ongoing efforts to develop treatments for chronic hepatitis B . The company highlighted progress with its lead siRNA therapeutic candidate, imdusiran, which demonstrated durable viral suppression and multiple functional cures in a Phase 2a clinical trial. The data showed meaningful reductions in both HBsAg and HBV DNA, with some patients able to discontinue therapy. Imdusiran was generally safe and well tolerated in the studies presented. Arbutus also reported a strong financial position, with cash and cash equivalents totaling $94 million as of September 30, 2025. The company is evaluating development plans for a Phase 2b clinical trial of imdusiran and continues to advance its immunotherapy program, including the oral PD-L1 inhibitor AB-101. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation","BK4139":"生物科技"},"translate_title":"Arbutus Biopharma公布慢性乙型肝炎功能性治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":0.9},"content_text":"Arbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B\n    \n\n        Arbutus Biopharma Corp. has provided an update on its ongoing efforts to develop treatments for chronic hepatitis B (cHBV). The company highlighted progress with its lead siRNA therapeutic candidate, imdusiran, which demonstrated durable viral suppression and multiple functional cures in a Phase 2a clinical trial. The data showed meaningful reductions in both HBsAg and HBV DNA, with some patients able to discontinue therapy. Imdusiran was generally safe and well tolerated in the studies presented. Arbutus also reported a strong financial position, with cash and cash equivalents totaling $94 million as of September 30, 2025. The company is evaluating development plans for a Phase 2b clinical trial of imdusiran and continues to advance its immunotherapy program, including the oral PD-L1 inhibitor AB-101. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583672355","isCrawlerRequest":true}